Miguel Á. Climent Durán

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

José Baselga, J. G. M. Segalla, Henri Roché et al. · Journal of Clinical Oncology · 2012 · 163 citations · Full text

Medicine, Oncology, Pharmacology +15

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma

David F. McDermott, Jae‐Lyun Lee, Georg A. Bjarnason et al. · Journal of Clinical Oncology · 2021 · 126 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

Joaquim Bellmunt, Andrea Necchi, Ronald de Wit et al. · Journal of Clinical Oncology · 2021 · 55 citations

Medicine, Oncology, Pharmacotherapy +16